SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or…
Secukinumab rapidly reduces hidden joint inflammation in psoriasis patients
Before joints become painful, psoriatic arthritis (PsA) often begins silently as enthesitis – inflammation where tendons and ligaments…
Biopsy-driven treatment strategy improves clinical outcomes in psoriatic arthritis
The management of psoriatic arthritis is increasingly focused on the early identification of clinical, immunological, and tissue-based phenotypes…
ICOTYDE Approval Adds New Growth Angle To Johnson & Johnson Valuation Story
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million…
Low-calorie diets linked to higher psoriatic arthritis risk, genetic study suggests
While often promoted for health benefits, low-calorie diets may carry hidden inflammatory risks, as genetic evidence reveals a…